In those with hearing loss, using hearing aids or cochlear implants was associated with a long-term reduction of cognitive decline by 19% and a 3% improvement in cognitive test scores.
Researchers identified two genes that respond to age-related iron accumulation in the substantia nigra. Knockdown of these genes results in severely impairing the cellular tolerance for iron toxicity.
A new blood test can detect toxic amyloid beta oligomers associated with Alzheimer's disease years before symptoms appear.
Researchers report abstaining from drinking alcohol can actually increase dementia risks. Low to moderate alcohol consumption may help to reduce dementia risks.
Lecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.
Media coverage of the FDA-approved Alzheimer's drug aducanumab made the public less willing to volunteer in Alzheimer's pharmaceutical trials.
Activating TREM2 on microglia in the brains of those with Alzheimer's could help slow down the progression of the neurodegenerative disease.
A subtle increase of the PKCα protein produces biochemical, cellular, and cognitive impairments akin to those seen in Alzheimer's disease. The finding provides a potential new target for the treatment of the neurodegenerative disorder.
Persistent asthma in adults was associated with increased inflammation and an excess build-up of plaques in the carotid arteries, increasing the risk of heart attack and stroke.
Researchers have identified two new genes, ATP8B4 and ABCA1, that are implicated in Alzheimer's disease. The genes impact the brain's immune system and cholesterol processing, leading to an increased risk of developing Alzheimer's disease.